Cantel Medical Corp.

Cantel Medical is a provider of infection prevention products and services in the healthcare market. The company has four segments: Medical, which designs, develops, manufactures, sells and installs products and services comprising a circle of infection prevention solutions; Life Sciences, which designs, develops, manufactures, sells, and installs water purification systems; Dental, which designs, manufactures, sells, supplies and distributes infection prevention healthcare products; and Dialysis, which designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers, as well as dialysate concentrates and supplies utilized for renal dialysis
  • TickerCMD
  • ISINUS1380981084
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States
CMD Cantel Medical ... (Health Care)

CANTEL MEDICAL CORP. sees a downgrade to Slightly Negative on account ...

The independent financial analyst theScreener just lowered the general evaluation of CANTEL MEDICAL CORP. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date June 4, 2021, the closing price was USD 80.37 and its target price was estimated at USD 63.46.

Valens Research
  • Valens Research
CMD Cantel Medical ... (Health Care)

CMD - Embedded Expectations Analysis - 2021 04 14

Cantel Medical Corp. (CMD:USA) currently trades below recent averages relative to UAFRS-based (Uniform) earnings, with a 22.0x Uniform P/E. At these levels, markets are pricing in bearish expectations for the firm, and management may have concerns about the pace of elective procedure recovery, Dental segment margins, and EPS and operating profit growth Specifically, management may lack confidence in their ability to sustain EPS growth, generate operating profit growth, and maintain wallet share gains with the complete circle of protection portfolio. In addition, they may have concerns about t...

CMD Cantel Medical ... (Health Care)

Cantel Medical Corp: 1 director bought

A director at Cantel Medical Corp bought 2,500 shares at 38.826USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of...

Jake Strole
  • Jake Strole
CMD Cantel Medical ... (Health Care)

Morningstar | Cantel Reports a Mixed Fiscal Third Quarter, but We Don'...

Narrow-moat Cantel Medical posted a mixed quarter, but overall results trended in line with our expectations. We intend to maintain our $86 per share fair value estimate, placing shares in 4-star territory. However, with a shifting management team and ongoing portfolio review, we'd highlight our high uncertainty rating for prospective investors. While overall revenue and earnings came in consistent with our expectations, outperformance in both the medical and dental segments overcame much weaker than projected results in the firm's water purification business. Organic growth of 12.2% in the m...

Jake Strole
  • Jake Strole
CMD Cantel Medical ... (Health Care)

Cantel Reports a Mixed Fiscal Third Quarter, but We Don't Expect a Cha...

Narrow-moat Cantel Medical posted a mixed quarter, but overall results trended in line with our expectations. We intend to maintain our $86 per share fair value estimate, placing shares in 4-star territory. However, with a shifting management team and ongoing portfolio review, we'd highlight our high uncertainty rating for prospective investors. While overall revenue and earnings came in consistent with our expectations, outperformance in both the medical and dental segments overcame much weaker...

Valens Research
  • Valens Research
CMD Cantel Medical ... (Health Care)

CMD - Embedded Expectations Analysis - 2021 04 14

Cantel Medical Corp. (CMD:USA) currently trades below recent averages relative to UAFRS-based (Uniform) earnings, with a 22.0x Uniform P/E. At these levels, markets are pricing in bearish expectations for the firm, and management may have concerns about the pace of elective procedure recovery, Dental segment margins, and EPS and operating profit growth Specifically, management may lack confidence in their ability to sustain EPS growth, generate operating profit growth, and maintain wallet share gains with the complete circle of protection portfolio. In addition, they may have concerns about t...

CMD Cantel Medical ... (Health Care)

Cantel Medical Corp: 1 director bought

A director at Cantel Medical Corp bought 2,500 shares at 38.826USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of...

Jake Strole
  • Jake Strole
CMD Cantel Medical ... (Health Care)

Morningstar | Cantel Reports a Mixed Fiscal Third Quarter, but We Don'...

Narrow-moat Cantel Medical posted a mixed quarter, but overall results trended in line with our expectations. We intend to maintain our $86 per share fair value estimate, placing shares in 4-star territory. However, with a shifting management team and ongoing portfolio review, we'd highlight our high uncertainty rating for prospective investors. While overall revenue and earnings came in consistent with our expectations, outperformance in both the medical and dental segments overcame much weaker than projected results in the firm's water purification business. Organic growth of 12.2% in the m...

Jake Strole
  • Jake Strole
CMD Cantel Medical ... (Health Care)

Cantel Reports a Mixed Fiscal Third Quarter, but We Don't Expect a Cha...

Narrow-moat Cantel Medical posted a mixed quarter, but overall results trended in line with our expectations. We intend to maintain our $86 per share fair value estimate, placing shares in 4-star territory. However, with a shifting management team and ongoing portfolio review, we'd highlight our high uncertainty rating for prospective investors. While overall revenue and earnings came in consistent with our expectations, outperformance in both the medical and dental segments overcame much weaker...

Jake Strole
  • Jake Strole
CMD Cantel Medical ... (Health Care)

Morningstar | Unexpected CEO Departure Doesn't Weaken Our Exemplary St...

Cantel Medical’s business has been transformed through acquisition since its breakup with former partner Olympus back in 2006, when both sides broke off distribution agreements with the goal of going direct in their respective markets. Since then, management’s strategy of buying regional businesses and scaling them nationally has thrived, with the firm now positioned as the leader in endoscope reprocessing and central water treatment for dialysis clinics across the country. This approach has built two narrow-moat business segments, in our view, that represent over 75% of total company sale...

CMD Cantel Medical ... (Health Care)

CANTEL MEDICAL CORP. sees a downgrade to Slightly Negative on account ...

The independent financial analyst theScreener just lowered the general evaluation of CANTEL MEDICAL CORP. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date June 4, 2021, the closing price was USD 80.37 and its target price was estimated at USD 63.46.

CMD Cantel Medical ... (Health Care)

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch